Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Development of orally active novel anti-cancer compounds targeting p53

Reference number
Coordinator Aprea AB
Funding from Vinnova SEK 1 065 310
Project duration June 2010 - November 2012
Status Completed

Last updated 25 November 2019

Reference number 2010-00386

Page statistics